JP5827220B2 - 人工多能性幹細胞の樹立効率改善方法 - Google Patents

人工多能性幹細胞の樹立効率改善方法 Download PDF

Info

Publication number
JP5827220B2
JP5827220B2 JP2012513400A JP2012513400A JP5827220B2 JP 5827220 B2 JP5827220 B2 JP 5827220B2 JP 2012513400 A JP2012513400 A JP 2012513400A JP 2012513400 A JP2012513400 A JP 2012513400A JP 5827220 B2 JP5827220 B2 JP 5827220B2
Authority
JP
Japan
Prior art keywords
myc
human
cells
seq
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2012513400A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013517758A (ja
JP2013517758A5 (enExample
Inventor
伸弥 山中
伸弥 山中
誠人 中川
誠人 中川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyoto University
Original Assignee
Kyoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto University filed Critical Kyoto University
Publication of JP2013517758A publication Critical patent/JP2013517758A/ja
Publication of JP2013517758A5 publication Critical patent/JP2013517758A5/ja
Application granted granted Critical
Publication of JP5827220B2 publication Critical patent/JP5827220B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/602—Sox-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/603—Oct-3/4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/604—Klf-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/605—Nanog
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/606—Transcription factors c-Myc
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C12N2501/608—Lin28

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2012513400A 2010-01-22 2011-01-21 人工多能性幹細胞の樹立効率改善方法 Active JP5827220B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28232010P 2010-01-22 2010-01-22
US61/282,320 2010-01-22
PCT/JP2011/051685 WO2011090221A1 (en) 2010-01-22 2011-01-21 Method for improving induced pluripotent stem cell generation efficiency

Publications (3)

Publication Number Publication Date
JP2013517758A JP2013517758A (ja) 2013-05-20
JP2013517758A5 JP2013517758A5 (enExample) 2014-03-06
JP5827220B2 true JP5827220B2 (ja) 2015-12-02

Family

ID=44307020

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012513400A Active JP5827220B2 (ja) 2010-01-22 2011-01-21 人工多能性幹細胞の樹立効率改善方法

Country Status (4)

Country Link
US (1) US9005967B2 (enExample)
EP (1) EP2526189B1 (enExample)
JP (1) JP5827220B2 (enExample)
WO (1) WO2011090221A1 (enExample)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9732319B2 (en) 2010-12-22 2017-08-15 Fate Therapeutics, Inc. Cell culture platform for single cell sorting and enhanced reprogramming of iPSCs
DK2951290T3 (en) 2013-02-01 2018-01-22 Us Health PROCEDURE FOR PREPARING RETINAL PIGMENTAL EPIT (RPE) CELLS FROM INDUCED PLURIPOTENT STEM CELLS (IPSCS)
EP3766962B1 (en) 2013-02-06 2025-10-22 University of Rochester Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
CN120536341A (zh) * 2014-03-04 2025-08-26 菲特治疗公司 改良的重编程方法和细胞培养平台
US9724432B2 (en) 2015-04-30 2017-08-08 University Of Rochester Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder
CN114807035B (zh) 2015-09-08 2024-02-02 (由卫生与公众服务部部长代表的)美利坚合众国 临床级别视网膜色素上皮细胞的可再现的分化方法
US11162070B2 (en) 2015-09-08 2021-11-02 FUJIFILM Cellular Dynamics, Inc. MACS-based purification of stem cell-derived retinal pigment epithelium
CN117737124A (zh) 2015-10-16 2024-03-22 菲特治疗公司 用于诱导和维护基态多能性的平台
WO2017070333A1 (en) 2015-10-20 2017-04-27 Cellular Dynamics International, Inc. Multi-lineage hematopoietic precursor cell production by genetic programming
AU2017290805B2 (en) 2016-07-01 2023-11-16 Research Development Foundation Elimination of proliferating cells from stem cell-derived grafts
EP3491134B1 (en) 2016-08-01 2023-10-11 University of Pittsburgh - of The Commonwealth System of Higher Education Human induced pluripotent stem cells for high efficiency genetic engineering
CA3038690A1 (en) 2016-10-05 2018-04-12 FUJIFILM Cellular Dynamics, Inc. Generating mature lineages from induced pluripotent stem cells with mecp2 disruption
US11458225B2 (en) 2016-11-09 2022-10-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 3D vascularized human ocular tissue for cell therapy and drug discovery
AU2018220843B2 (en) 2017-02-14 2023-09-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods of engineering human induced pluripotent stem cells to produce liver tissue
CN110891967B (zh) 2017-04-18 2025-03-14 富士胶片细胞动力公司 抗原特异性免疫效应细胞
JP2020517259A (ja) 2017-04-19 2020-06-18 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 操作された抗原受容体を発現する免疫細胞
EP3621434B1 (en) 2017-05-10 2026-07-15 University of Rochester Glial progenitor cells for use in treating schizophrenia
WO2019204817A1 (en) 2018-04-20 2019-10-24 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
CN112566640A (zh) 2018-06-18 2021-03-26 罗切斯特大学 治疗精神分裂症和其他神经精神病症的方法
US12303549B2 (en) 2018-06-21 2025-05-20 University Of Rochester Methods of treating or inhibiting onset of Huntington's disease
CN112912492A (zh) * 2018-07-02 2021-06-04 林希龙 活体外诱导成体干细胞增殖及分化
CA3119041A1 (en) 2018-11-19 2020-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Biodegradable tissue replacement implant and its use
AU2019386140B2 (en) 2018-11-28 2026-05-28 Board Of Regents, The University Of Texas System Multiplex genome editing of immune cells to enhance functionality and resistance to suppressive environment
EP3886874B1 (en) 2018-11-29 2024-12-11 Board of Regents, The University of Texas System Methods for ex vivo expansion of natural killer cells and use thereof
AU2019396450B2 (en) 2018-12-11 2025-08-28 University Of Rochester Methods of treating schizophrenia and other neuropsychiatric disorders
EP3923962A2 (en) 2019-02-13 2021-12-22 University of Rochester Gene networks that mediate remyelination of the human brain
WO2021092657A1 (en) 2019-11-13 2021-05-20 Monash University Methods for reprogramming cells
EP4118234A1 (en) 2020-03-09 2023-01-18 FUJIFILM Corporation Markers specific for pluripotent stem cells, and methods of using the same
IL298254A (en) 2020-05-29 2023-01-01 Fujifilm Cellular Dynamics Inc Double layer of retinal pigment epithelium and photoreceptors and their uses
KR20230019453A (ko) 2020-05-29 2023-02-08 후지필름 셀룰러 다이내믹스, 인코포레이티드 망막 색소 상피 세포 및 광수용체의 이중 세포 응집체 및 이의 사용 방법
CA3201499A1 (en) 2020-11-13 2022-05-19 Catamaran Bio, Inc. Genetically modified natural killer cells and methods of use thereof
JP2023550453A (ja) 2020-11-18 2023-12-01 富士フイルム株式会社 セクレトーム含有組成物の生成、並びにその使用及び分析方法
US12060581B2 (en) 2020-11-24 2024-08-13 Monash University Methods and cellular structures
AU2021389671A1 (en) 2020-11-24 2023-06-22 Monash University Induced stem cells
EP4251645A1 (en) 2020-11-25 2023-10-04 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
US20220306991A1 (en) 2021-03-25 2022-09-29 Bluerock Therapeutics Lp Methods for obtaining induced pluripotent stem cells
WO2022251443A1 (en) 2021-05-26 2022-12-01 FUJIFILM Cellular Dynamics, Inc. Methods to prevent rapid silencing of genes in pluripotent stem cells
WO2022251499A1 (en) 2021-05-28 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods to generate macular, central and peripheral retinal pigment epithelial cells
JP2024520423A (ja) 2021-05-28 2024-05-24 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 弱接着細胞を収容するための二次マトリックスを有する生分解性組織スキャフォールド
EP4402249A1 (en) 2021-09-13 2024-07-24 Fujifilm Cellular Dynamics, Inc. Methods for the production of committed cardiac progenitor cells
US20230241118A1 (en) 2021-10-20 2023-08-03 University Of Rochester Rejuvenation treatment of age-related white matter loss
CA3235105A1 (en) 2021-10-20 2023-04-27 Steven A. Goldman Humanized chimeras for the prospective assessment of glial cell addition or replacement therapy
US20230226116A1 (en) 2021-10-20 2023-07-20 University Of Rochester Method for rejuvenating glial progenitor cells and rejuvenated glial progenitor cells per se
CA3236365A1 (en) 2021-11-02 2023-05-11 University Of Rochester Tcf7l2 mediated remyelination in the brain
US20250161495A1 (en) 2022-02-01 2025-05-22 University Of Rochester Methods of generating a population of neurons from human glial progenitor cells and genetic constructs for carrying out such methods
WO2023172514A1 (en) 2022-03-07 2023-09-14 Catamaran Bio, Inc. Engineered immune cell therapeutics targeted to her2 and methods of use thereof
WO2023215455A1 (en) 2022-05-05 2023-11-09 University Of Rochester Dual macroglial-microglial approach towards therapeutic cell replacement in neurodegenerative and neuropsychiatric disease
US20240003871A1 (en) 2022-06-29 2024-01-04 FUJIFILM Cellular Dynamics, Inc. Ipsc-derived astrocytes and methods of use thereof
WO2024073776A1 (en) 2022-09-30 2024-04-04 FUJIFILM Cellular Dynamics, Inc. Methods for the production of cardiac fibroblasts
EP4658294A2 (en) 2023-02-02 2025-12-10 University of Rochester Competitive replacement of glial cells
WO2024192329A1 (en) 2023-03-16 2024-09-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for producing stable human chondroctyes and their use for promoting cartillage growth and repair
WO2025245202A1 (en) 2024-05-21 2025-11-27 FUJIFILM Cellular Dynamics, Inc. Particle counting and biomass measurements of aggregated cell compositions
US20260146229A1 (en) 2024-11-27 2026-05-28 Bluerock Therapeutics Lp Photoreceptor precursor cell (prp) compositions and uses thereof
WO2026117659A1 (en) 2024-11-27 2026-06-04 Bluerock Therapeutics Lp Methods of treating inherited retinal diseases
US20260226420A1 (en) 2025-01-31 2026-08-06 FUJIFILM Holdings America Corporation Methods for the production of hepatic stellate cells from human pluripotent stem cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4937190A (en) 1987-10-15 1990-06-26 Wisconsin Alumni Research Foundation Translation enhancer
ES2296413T3 (es) 1998-06-08 2008-04-16 Osiris Therapeutics, Inc. Regulacion de la diferenciacion de celulas madre hematopoyeticas por el uso de celulas madre mesenquimaticas humanas.
WO2000070070A1 (en) 1999-05-18 2000-11-23 Dnavec Research Inc. Paramyxoviridae virus vector defective in envelope gene
US6602711B1 (en) 2000-02-21 2003-08-05 Wisconsin Alumni Research Foundation Method of making embryoid bodies from primate embryonic stem cells
JP3660601B2 (ja) 2001-03-30 2005-06-15 独立行政法人科学技術振興機構 胚性幹細胞からの神経幹細胞、運動ニューロン及びｇａｂａ作動性ニューロンの製造法
JP2004121165A (ja) 2002-10-07 2004-04-22 Asahi Kasei Corp 膵幹様細胞の分化誘導方法
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
DK3399025T3 (da) 2007-03-23 2025-06-16 Wisconsin Alumni Res Found Omprogrammering af somatiske celler
AU2008297024B2 (en) 2007-10-31 2014-08-28 Kyoto University Nuclear reprogramming method

Also Published As

Publication number Publication date
EP2526189A4 (en) 2014-03-19
US20120276636A1 (en) 2012-11-01
JP2013517758A (ja) 2013-05-20
EP2526189B1 (en) 2016-10-12
WO2011090221A1 (en) 2011-07-28
US9005967B2 (en) 2015-04-14
EP2526189A1 (en) 2012-11-28

Similar Documents

Publication Publication Date Title
EP2526189B1 (en) Method for improving induced pluripotent stem cell generation efficiency
JP5765746B2 (ja) 効率的な人工多能性幹細胞の樹立方法
JP5553289B2 (ja) 新規核初期化物質
JP5888753B2 (ja) 効率的な人工多能性幹細胞の樹立方法
US9506039B2 (en) Efficient method for establishing induced pluripotent stem cells
US20110003365A1 (en) Method of preparing induced pluripotent stem cells deprived of reprogramming gene
JP5773393B2 (ja) 効率的な人工多能性幹細胞の樹立方法
KR101564044B1 (ko) 핵초기화 방법
WO2011055851A1 (en) Method of efficiently establishing induced pluripotent stem cells
WO2011158967A1 (en) Method for efficiently establishing induced pluripotent stem cell
WO2013031826A1 (ja) 核初期化物質

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150324

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20151006

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20151015

R150 Certificate of patent or registration of utility model

Ref document number: 5827220

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250